LT3118311T - Priešprasminė nukleorūgštis - Google Patents

Priešprasminė nukleorūgštis

Info

Publication number: LT3118311T
Authority: LT; Lithuania
Prior art keywords: nucleic acid; antisense nucleic; antisense; acid; nucleic
Prior art date: 2014-03-12

Application number

LTEP15761392.8T

Other languages

English (en)

Inventor

Tatsushi Wakayama

Haruna Seo

Youhei Satou

Shin`ichi TAKEDA

Tetsuya Nagata

Original Assignee

Nippon Shinyaku Co., Ltd.

National Center Of Neurology And Psychiatry

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-12

Filing date

2015-03-11

Publication date

2019-04-10

2015-03-11 Application filed by Nippon Shinyaku Co., Ltd., National Center Of Neurology And Psychiatry filed Critical Nippon Shinyaku Co., Ltd.

2019-04-10 Publication of LT3118311T publication Critical patent/LT3118311T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3535—Nitrogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LTEP15761392.8T 2014-03-12 2015-03-11 Priešprasminė nukleorūgštis LT3118311T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2014048897		2014-03-12
PCT/JP2015/057180 WO2015137409A1 (ja)	2014-03-12	2015-03-11	アンチセンス核酸

Publications (1)

Publication Number	Publication Date
LT3118311T true LT3118311T (lt)	2019-04-10

Family

ID=54071850

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP15761392.8T LT3118311T (lt)	2014-03-12	2015-03-11	Priešprasminė nukleorūgštis

Country Status (31)

Country	Link
US (5)	US9988629B2 (lt)
EP (2)	EP3514234A1 (lt)
JP (1)	JP6606488B2 (lt)
KR (1)	KR102335801B1 (lt)
CN (2)	CN106459955B (lt)
AU (2)	AU2015227733B2 (lt)
BR (1)	BR112016020618B1 (lt)
CA (1)	CA2939948A1 (lt)
CY (1)	CY1121322T1 (lt)
DK (1)	DK3118311T3 (lt)
ES (1)	ES2710802T3 (lt)
HR (1)	HRP20190235T1 (lt)
HU (1)	HUE042283T2 (lt)
IL (1)	IL247663B (lt)
LT (1)	LT3118311T (lt)
MX (1)	MX2016011538A (lt)
MY (1)	MY193708A (lt)
NZ (1)	NZ724836A (lt)
PH (1)	PH12016501761A1 (lt)
PL (1)	PL3118311T3 (lt)
PT (1)	PT3118311T (lt)
RS (1)	RS58573B1 (lt)
RU (2)	RU2702424C2 (lt)
SG (1)	SG11201607095RA (lt)
SI (1)	SI3118311T1 (lt)
SM (1)	SMT201900169T1 (lt)
TR (1)	TR201901939T4 (lt)
TW (2)	TW201945383A (lt)
UA (1)	UA120849C2 (lt)
WO (1)	WO2015137409A1 (lt)
ZA (1)	ZA201605864B (lt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112016020618B1 (pt) *	2014-03-12	2023-04-04	Nippon Shinyaku Co., Ltd.	Oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
RS59764B1 (sr)	2014-06-17	2020-02-28	Nippon Shinyaku Co Ltd	Antismisaona nukleinska kiselina za upotrebu u lečenju dišenove mišićne distrofije
JP6384845B2 (ja)	2015-09-15	2018-09-05	日本新薬株式会社	アンチセンス核酸
KR20180056766A (ko)	2015-10-09	2018-05-29	웨이브 라이프 사이언시스 리미티드	뉴클레오티드 조성물 및 이의 방법
MA45328A (fr)	2016-04-01	2019-02-06	Avidity Biosciences Llc	Compositions acide nucléique-polypeptide et utilisations de celles-ci
EP3478697A1 (en)	2016-06-30	2019-05-08	Sarepta Therapeutics, Inc.	Exon skipping oligomers for muscular dystrophy
EP3485015A4 (en) *	2016-07-15	2020-07-29	Ionis Pharmaceuticals, Inc.	COMPOUNDS AND METHODS OF MODULATION OF DYSTROPHINE TRANSCRIPT
CA3037663A1 (en) *	2016-09-23	2018-03-29	Synthena Ag	Mixed tricyclo-dna, 2'-modified-rna oligonucleotide compositions and uses thereof
DK3554552T3 (da)	2016-12-19	2022-10-24	Sarepta Therapeutics Inc	Exon-skipping-oligomerkonjugater mod muskeldystrofi
LT3554553T (lt)	2016-12-19	2022-08-25	Sarepta Therapeutics, Inc.	Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos
PL3554554T3 (pl)	2016-12-19	2022-12-19	Sarepta Therapeutics, Inc.	Koniugaty oligomerów z pominięciem egzonu w dystrofii mięśniowej
SG10202107429WA (en) *	2017-01-06	2021-08-30	Avidity Biosciences Inc	Nucleic acid-polypeptide compositions and methods of inducing exon skipping
GB201711809D0 (en)	2017-07-21	2017-09-06	Governors Of The Univ Of Alberta	Antisense oligonucleotide
EA201991450A1 (ru)	2017-09-22	2019-12-30	Сарепта Терапьютикс, Инк.	Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
ES2963336T3 (es) *	2017-09-25	2024-03-26	Sarepta Therapeutics Inc	Procesos para preparar oligómeros de fosforodiamidato morfolino mediante síntesis de flujo rápido
US20200248178A1 (en)	2017-09-28	2020-08-06	Sarepta Therapeutics, Inc.	Combination therapies for treating muscular dystrophy
TWI844541B (zh)	2018-05-11	2024-06-11	新加坡商波濤生命科學有限公司	寡核苷酸組成物及其使用方法
US10765760B2 (en)	2018-05-29	2020-09-08	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
WO2019240223A1 (ja) *	2018-06-13	2019-12-19	公益財団法人川崎市産業振興財団	数平均分子量が３ｋＤａ～１０ｋＤａであるＰＥＧブロックとカチオン性ポリマーとのブロックコポリマーと、アンチセンスオリゴヌクレオチドとを含む、ポリイオンコンプレックスミセル
US11168141B2 (en)	2018-08-02	2021-11-09	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20220193250A1 (en)	2018-08-02	2022-06-23	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12018087B2 (en)	2018-08-02	2024-06-25	Dyne Therapeutics, Inc.	Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
SG11202100934PA (en)	2018-08-02	2021-02-25	Dyne Therapeutics Inc	Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020089325A1 (en) *	2018-11-02	2020-05-07	Biomarin Technologies B.V.	Bispecific antisense oligonucleotides for dystrophin exon skipping
JP2022513719A (ja) *	2018-12-06	2022-02-09	ウェイブライフサイエンシズリミテッド	オリゴヌクレオチド組成物及びその方法
WO2020158792A1 (ja) *	2019-01-30	2020-08-06	国立研究開発法人国立精神・神経医療研究センター	核酸送達複合体
US12497615B2 (en)	2019-04-25	2025-12-16	Avidity Biosciences, Inc.	Nucleic acid compositions and methods of multi-exon skipping
KR20220145865A (ko)	2020-02-28	2022-10-31	니뽄 신야쿠 가부시키가이샤	엑손 51의 스키핑을 유도하는 안티센스 핵산
US12286630B2 (en)	2021-04-30	2025-04-29	Sarepta Therapeutics, Inc.	Treatment methods for muscular dystrophy
US11969475B2 (en)	2021-07-09	2024-04-30	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en)	2021-07-09	2023-10-03	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en)	2021-07-09	2023-05-02	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
AU2022309028A1 (en)	2021-07-09	2024-01-25	Dyne Therapeutics, Inc.	Muscle targeting complexes and formulations for treating dystrophinopathies
WO2023127918A1 (ja)	2021-12-27	2023-07-06	日本新薬株式会社	オリゴ核酸化合物の製造方法
TW202346589A (zh)	2022-03-10	2023-12-01	日商日本新藥股份有限公司	抗病毒反義寡聚物
CN119013401A (zh)	2022-03-17	2024-11-22	萨勒普塔医疗公司	二氨基磷酸酯吗啉代寡聚物缀合物
US12071621B2 (en)	2022-04-05	2024-08-27	Avidity Biosciences, Inc.	Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
EP0506830B1 (en)	1989-12-20	2005-12-14	Avi Biopharma, Inc.	Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
JP2924179B2 (ja)	1993-02-19	1999-07-26	日本新薬株式会社	グリセロール誘導体，デバイス及び医薬組成物
IL115849A0 (en)	1994-11-03	1996-01-31	Merz & Co Gmbh & Co	Tangential filtration preparation of liposomal drugs and liposome product thereof
EP1191097A1 (en)	2000-09-21	2002-03-27	Leids Universitair Medisch Centrum	Induction of exon skipping in eukaryotic cells
CA2507125C (en) *	2002-11-25	2014-04-22	Masafumi Matsuo	Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors
SI1766010T1 (sl) *	2004-06-28	2011-06-30	Univ Western Australia	Protismiselni oligonukleotidi za induciranje preskakovanja eksonov in postopki za njihovo uporabo
EP1811024A1 (en)	2004-10-05	2007-07-25	Nippon Shinyaku Co., Ltd.	Oligo double-stranded rna and medicinal composition
CA2605512A1 (en) *	2005-04-22	2006-10-26	Academisch Ziekenhuis Leiden	Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secondary rna structure.
US20090069260A1 (en)	2005-05-30	2009-03-12	Nippon Shinyaku Co., Ltd	Method for producing a nucleic-acid-containing complex preparation
US8067571B2 (en) *	2005-07-13	2011-11-29	Avi Biopharma, Inc.	Antibacterial antisense oligonucleotide and method
RU2418068C2 (ru) *	2005-08-17	2011-05-10	Сирна Терапьютикс, Инк.	Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк
WO2007145661A2 (en) *	2005-11-30	2007-12-21	Guild Associates, Inc.	Differentially fluorescent yeast biosensors for the detection and biodegradation of chemical agents
JP5347510B2 (ja)	2007-02-05	2013-11-20	日本新薬株式会社	ポリエチレングリコール誘導体
PL2203173T3 (pl)	2007-10-26	2016-06-30	Academisch Ziekenhuis Leiden	Środki i sposoby przeciwdziałania zaburzeniom mięśni
HRP20140646T1 (hr)	2007-11-15	2014-09-26	Sarepta Therapeutics, Inc.	Postupak sinteze morfolino oligomera
US8084601B2 (en)	2008-09-11	2011-12-27	Royal Holloway And Bedford New College Royal Holloway, University Of London	Oligomers
CA3066050A1 (en) *	2008-10-24	2010-04-29	Sarepta Therapeutics, Inc.	Multiple exon skipping compositions for dmd
CA2741629C (en)	2008-10-27	2022-07-05	Academisch Ziekenhuis Leiden	Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna
US20110269665A1 (en)	2009-06-26	2011-11-03	Avi Biopharma, Inc.	Compound and method for treating myotonic dystrophy
WO2011057350A1 (en) *	2009-11-12	2011-05-19	The University Of Western Australia	Antisense molecules and methods for treating pathologies
TWI620756B (zh) *	2010-05-28	2018-04-11	薩羅塔治療公司	具有經修飾之單元間連結及／或末端基團之寡核苷酸類似物
IT1400425B1 (it) *	2010-06-08	2013-05-31	Amsterdam Molecular Therapeutics Bv	Modified snrnas for use in therapy.
TWI541024B (zh) *	2010-09-01	2016-07-11	日本新藥股份有限公司	反義核酸
MX2013009191A (es) *	2011-02-08	2013-11-04	Charlotte Mecklenburg Hospital	Oligonucleotidos antisentido.
KR102229650B1 (ko) *	2011-05-05	2021-03-19	사렙타 쎄러퓨틱스, 인코퍼레이티드	펩타이드 올리고뉴클레오타이드 접합체
CN117721110A (zh) *	2011-12-28	2024-03-19	日本新药株式会社	反义核酸
BR112016020618B1 (pt) *	2014-03-12	2023-04-04	Nippon Shinyaku Co., Ltd.	Oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido

2015
- 2015-03-11 BR BR112016020618-5A patent/BR112016020618B1/pt active IP Right Grant
- 2015-03-11 SI SI201530597T patent/SI3118311T1/sl unknown
- 2015-03-11 JP JP2016507800A patent/JP6606488B2/ja active Active
- 2015-03-11 RU RU2016139108A patent/RU2702424C2/ru active
- 2015-03-11 LT LTEP15761392.8T patent/LT3118311T/lt unknown
- 2015-03-11 WO PCT/JP2015/057180 patent/WO2015137409A1/ja not_active Ceased
- 2015-03-11 SM SM20190169T patent/SMT201900169T1/it unknown
- 2015-03-11 US US15/122,435 patent/US9988629B2/en active Active
- 2015-03-11 RS RS20190188A patent/RS58573B1/sr unknown
- 2015-03-11 KR KR1020167027723A patent/KR102335801B1/ko active Active
- 2015-03-11 AU AU2015227733A patent/AU2015227733B2/en active Active
- 2015-03-11 SG SG11201607095RA patent/SG11201607095RA/en unknown
- 2015-03-11 MX MX2016011538A patent/MX2016011538A/es active IP Right Grant
- 2015-03-11 HU HUE15761392A patent/HUE042283T2/hu unknown
- 2015-03-11 CA CA2939948A patent/CA2939948A1/en active Pending
- 2015-03-11 CN CN201580012727.4A patent/CN106459955B/zh active Active
- 2015-03-11 PT PT15761392T patent/PT3118311T/pt unknown
- 2015-03-11 DK DK15761392.8T patent/DK3118311T3/en active
- 2015-03-11 TW TW108129128A patent/TW201945383A/zh unknown
- 2015-03-11 CN CN201911163414.5A patent/CN110951732A/zh active Pending
- 2015-03-11 TR TR2019/01939T patent/TR201901939T4/tr unknown
- 2015-03-11 NZ NZ724836A patent/NZ724836A/en unknown
- 2015-03-11 PL PL15761392T patent/PL3118311T3/pl unknown
- 2015-03-11 UA UAA201610167A patent/UA120849C2/uk unknown
- 2015-03-11 MY MYPI2016703281A patent/MY193708A/en unknown
- 2015-03-11 HR HRP20190235TT patent/HRP20190235T1/hr unknown
- 2015-03-11 EP EP18205909.7A patent/EP3514234A1/en active Pending
- 2015-03-11 EP EP15761392.8A patent/EP3118311B1/en active Active
- 2015-03-11 RU RU2019130513A patent/RU2730681C2/ru active
- 2015-03-11 TW TW104107708A patent/TWI672314B/zh active
- 2015-03-11 ES ES15761392T patent/ES2710802T3/es active Active
2016
- 2016-08-23 ZA ZA2016/05864A patent/ZA201605864B/en unknown
- 2016-09-06 IL IL247663A patent/IL247663B/en active IP Right Grant
- 2016-09-07 PH PH12016501761A patent/PH12016501761A1/en unknown
2018
- 2018-02-22 US US15/902,231 patent/US20180179538A1/en not_active Abandoned
2019
- 2019-02-12 CY CY20191100184T patent/CY1121322T1/el unknown
- 2019-06-11 US US16/437,130 patent/US11053497B2/en active Active
2020
- 2020-01-30 AU AU2020200679A patent/AU2020200679B2/en active Active
2021
- 2021-06-30 US US17/364,618 patent/US20220162604A1/en not_active Abandoned
2024
- 2024-11-19 US US18/951,766 patent/US20250145997A1/en active Pending

Also Published As

Publication number	Publication date
RS58573B1 (sr)	2019-05-31
EP3514234A1 (en)	2019-07-24
TR201901939T4 (tr)	2019-03-21
PH12016501761B1 (en)	2016-11-07
US11053497B2 (en)	2021-07-06
HUE042283T2 (hu)	2019-06-28
TW201540724A (zh)	2015-11-01
JPWO2015137409A1 (ja)	2017-04-06
PH12016501761A1 (en)	2016-11-07
CN110951732A (zh)	2020-04-03
SMT201900169T1 (it)	2019-05-10
TWI672314B (zh)	2019-09-21
US20250145997A1 (en)	2025-05-08
PL3118311T3 (pl)	2019-09-30
US20180179538A1 (en)	2018-06-28
RU2016139108A (ru)	2018-04-13
PT3118311T (pt)	2019-02-15
IL247663B (en)	2020-06-30
AU2020200679B2 (en)	2022-03-10
MX2016011538A (es)	2017-04-13
SI3118311T1 (sl)	2019-05-31
CY1121322T1 (el)	2020-05-29
WO2015137409A1 (ja)	2015-09-17
US20170067048A1 (en)	2017-03-09
CA2939948A1 (en)	2015-09-17
JP6606488B2 (ja)	2019-11-13
DK3118311T3 (en)	2019-03-11
IL247663A0 (en)	2016-11-30
ZA201605864B (en)	2018-12-19
RU2019130513A3 (lt)	2020-03-13
UA120849C2 (uk)	2020-02-25
EP3118311A4 (en)	2017-10-11
US20200149040A1 (en)	2020-05-14
AU2015227733A1 (en)	2016-10-20
CN106459955B (zh)	2019-12-20
ES2710802T3 (es)	2019-04-26
RU2019130513A (ru)	2019-10-10
RU2702424C2 (ru)	2019-10-08
US9988629B2 (en)	2018-06-05
KR102335801B1 (ko)	2021-12-03
NZ724836A (en)	2022-07-01
BR112016020618A2 (pt)	2017-08-15
US20220162604A1 (en)	2022-05-26
AU2020200679A1 (en)	2020-02-20
RU2730681C2 (ru)	2020-08-24
EP3118311A1 (en)	2017-01-18
RU2016139108A3 (lt)	2018-08-06
SG11201607095RA (en)	2016-10-28
BR112016020618B1 (pt)	2023-04-04
EP3118311B1 (en)	2018-12-26
MY193708A (en)	2022-10-26
BR112016020618A8 (pt)	2021-07-13
CN106459955A (zh)	2017-02-22
TW201945383A (zh)	2019-12-01
AU2015227733B2 (en)	2019-10-31
KR20160132056A (ko)	2016-11-16
HRP20190235T1 (hr)	2019-05-03

Publication	Publication Date	Title
SMT201900169T1 (it)	2019-05-10	Acido nucleico antisenso
ZA201700142B (en)	2020-05-27	Antisense nucleic acids
DK3134131T3 (en)	2022-02-07	Nucleic acid vaccines
SG11201802138TA (en)	2018-04-27	Antisense nucleic acid
GB201507119D0 (en)	2015-06-10	Nucleic Acid Construct
GB201507115D0 (en)	2015-06-10	Nucleic Acid Construct
GB201507111D0 (en)	2015-06-10	Nucleic acid construct
GB201507104D0 (en)	2015-06-10	Nucleic acid construct
GB201507108D0 (en)	2015-06-10	Nucleic acid construct
GB201405226D0 (en)	2014-05-07	Nucleic acid preparation method
GB201408841D0 (en)	2014-07-02	Nucleic acid processing
GB201517241D0 (en)	2015-11-11	DNA modification
IL257500A (en)	2018-04-30	Altered cullin1 gene